Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

2019

DISCLOSURES: Selleslag: Celyad: Other: Clinical trial research (no honoraria recieved); Novartis: Consultancy, Honoraria, Speakers Bureau.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

0

References

2

Citations